| 11th week of 2013 patent applcation highlights part 46 |
| Patent application number | Title | Published |
|---|
| 20130065862 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES - A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food. | 2013-03-14 |
| 20130065863 | NITROXYL (HNO) RELEASING COMPOUNDS AND USES THEREOF IN TREATING DISEASES - Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof: (I) in which R | 2013-03-14 |
| 20130065864 | NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS - The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds. | 2013-03-14 |
| 20130065865 | BARRIER FILM-FORMING GERMICIDAL COMPOSITION FOR CONTROLLING MASTITIS - A long-lasting persistent, uniform film-forming skin protecting germicidal composition provides a long-lasting persistent barrier film when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis. A barrier film-forming agent is selected from the modified or hydrolyzed polysaccharides, particularly a hydrolyzed or modified starch, such as dextrin and maltodextrin. The barrier film-forming agent is stably solubilized in a solvent that dries to form the long-lasting persistent uniform film over the animal skin. The compositions also contain antimicrobial agents that fight against microbes that manage to penetrate the protective barrier film. Particularly, advantageous is that all the materials used are safe food additive and cost effective over the traditional barrier film forming agents. | 2013-03-14 |
| 20130065866 | DENTINAL DRUG DELIVERY COMPOSITION AND SCREENING METHOD - The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent, a method for using the dentinal drug delivery to provide a dental treatment, and a method for identifying anti-inflammatory agents capable of diffusing through dentin. | 2013-03-14 |
| 20130065867 | Compositions and methods for using same for treating posterior blepharitis - This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids. | 2013-03-14 |
| 20130065868 | ANXIOYTIC MARCGRAVIACEAE COMPOSITIONS CONTAINING BETULINIC ACID, BETULINIC ACID DERIVATIVES, AND METHODS - Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject. | 2013-03-14 |
| 20130065869 | OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD - Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier. | 2013-03-14 |
| 20130065870 | TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users. | 2013-03-14 |
| 20130065871 | EMULSION COMPOSITION - An object of the present invention is to provide an emulsion composition that keeps smooth texture due to methyl polysiloxane, prevents the crystal precipitation of macadamia nut oil fatty acid phytosteryl to enhance formulation stability, and has a superior effect of conferring a resilient feel and emollient property. The present invention relates to an emulsion composition comprising (A) macadamia nut oil fatty acid phytosteryl, (B) methyl polysiloxane, and (C) one or more oils selected from the group consisting of glyceryl tri(2-ethylhexanoate), methylphenyl polysiloxane, cetyl ethylhexanoate, pentaerythrityl tetraethylhexanoate, and tripropylene glycol pivalate, wherein the content ratio of (A) to (C), (A):(C), is 1:3 to 1:200. | 2013-03-14 |
| 20130065872 | SYNTHESIS OF SYRBACTIN PROTEASOME INHIBITORS - The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs. | 2013-03-14 |
| 20130065873 | METAL COMPLEXES - The present invention relates, inter alia, to metal complexes having improved solubility, process for the preparation of the metal complexes, devices comprising these metal complexes, and the use of the metal complexes. | 2013-03-14 |
| 20130065874 | METHODS FOR TREATING INTRAPULMONARY INFECTIONS - This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane. | 2013-03-14 |
| 20130065875 | SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS - The invention provides derivatives and analogues of triazatetracyclo[7.7.0.0 | 2013-03-14 |
| 20130065876 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES - The present invention relates to compounds of formula I, | 2013-03-14 |
| 20130065877 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (Ia) and formula (Ib). | 2013-03-14 |
| 20130065878 | CELL-FREE PREPARATION OF CARBAPENEMS - Provided herein are cell-free systems for generating carbapenems, e.g., a compound of the Formula (I): | 2013-03-14 |
| 20130065879 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-03-14 |
| 20130065880 | COMPOUNDS AS TYROSINE KINASE MODULATORS - The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors. | 2013-03-14 |
| 20130065881 | Tricyclic Compounds for Use as Kinase Inhibitors - There is provided compounds of formula (I), wherein R | 2013-03-14 |
| 20130065882 | VLA-4 inhibitory drug - This invention relates to a VLA-4 inhibitory drug, having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally, wherein an active ingredient is represented by formula (I), or a salt thereof: | 2013-03-14 |
| 20130065883 | Triazolo [4, 5- B] Pyridin Derivatives - There is provided compounds of formula (I), wherein R | 2013-03-14 |
| 20130065884 | Anti-Infective Compounds - The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis. | 2013-03-14 |
| 20130065885 | ORAL THERAPEUTIC COMPOUND DELIVERY SYSTEM - The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system. | 2013-03-14 |
| 20130065886 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS - The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions. | 2013-03-14 |
| 20130065887 | Treatment of Cancer with Dopamine Receptor Antagonists - Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided. Also described are methods for the identification and validation of agents that target cancer stem cells. | 2013-03-14 |
| 20130065888 | OPHTHALMIC FORMULATIONS AND PROCESSES FOR THEIR PREPARATION - The invention relates to a process for preparing ophthalmic formulations and to formulations containing a suspension of an ophthalmic drug in an aqueous vehicle. The invention further relates to the production of stable ophthalmic formulations that have a minimal propensity to form drug aggregates. | 2013-03-14 |
| 20130065889 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS - Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists, e.g., compounds of Formula I, and pharmaceutical compositions thereof: Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition. | 2013-03-14 |
| 20130065890 | PYRIMIDINE DERIVATIVES - A compound of the following formula: | 2013-03-14 |
| 20130065891 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE - A plant disease control composition comprising a carboxamide compound represented by following formula (I), wherein R | 2013-03-14 |
| 20130065892 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-03-14 |
| 20130065893 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein the variables R | 2013-03-14 |
| 20130065894 | 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, | 2013-03-14 |
| 20130065895 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction - Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. | 2013-03-14 |
| 20130065896 | FUSED IMIDAZOLE DERIVATIVE - Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product. | 2013-03-14 |
| 20130065897 | COMPOUNDS, PREPARATION AND USES THEREOF - The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity. | 2013-03-14 |
| 20130065898 | USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS - The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs. | 2013-03-14 |
| 20130065899 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-03-14 |
| 20130065900 | PHARMACEUTICAL COMPOUNDS - The invention provides a compound of the formula (1): | 2013-03-14 |
| 20130065901 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS - Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. | 2013-03-14 |
| 20130065902 | 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS - The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I), | 2013-03-14 |
| 20130065903 | Method of Improving Diastolic Dysfunction - A method of treating, preventing, reversing, or ameliorating diastolic dysfunction includes reducing S-glutathionylated myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH | 2013-03-14 |
| 20130065904 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders - One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. | 2013-03-14 |
| 20130065905 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE - The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): | 2013-03-14 |
| 20130065906 | New compounds, pharmaceutical compositions and uses thereof - The present invention relates to compounds of general formula I, | 2013-03-14 |
| 20130065907 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES - The present invention relates to compounds of the formula | 2013-03-14 |
| 20130065908 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: | 2013-03-14 |
| 20130065909 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES - The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative. | 2013-03-14 |
| 20130065910 | ORAL MECLIZINE AQUEOUS FORMULATIONS WITH TASTE FLAVORING AGENT - An oral meclizine aqueous formulation is disclosed. The oral meclizine aqueous formulation comprises a solubizier for enhancing aqueous solubility of meclizine, and a taster flavoring agent selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium, stevioside, and their mixtures. Preferably the solubilizer is hydroxypropyl-β-cyclodextrin or polyethylene glycol 660 13-hydroxystearate. The oral meclizine aqueous formulation can provide a rapid onset of therapeutic effects of meclizine. | 2013-03-14 |
| 20130065911 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES - The present invention relates to compounds of the formula | 2013-03-14 |
| 20130065912 | PESTICIDAL COMPOSITIONS - Pesticide compositions and their use in controlling pests are provided. | 2013-03-14 |
| 20130065913 | NOVEL COMPOUNDS - Compounds of formula (I): | 2013-03-14 |
| 20130065914 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 2013-03-14 |
| 20130065915 | NOVEL FORMULATION - The present invention provides a liquid formulation comprising a strobilurin fungicide, such as azoxystrobin, at least one non-ionic surfactant, at least one anionic surfactant and a solvent/carrier. | 2013-03-14 |
| 20130065916 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND - The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms. | 2013-03-14 |
| 20130065917 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE - 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy. | 2013-03-14 |
| 20130065918 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - The present invention relates to compounds of formula (I): | 2013-03-14 |
| 20130065919 | SUBSTITUTED N-ALKYL AND N-ACYL TETRAHYDRO-ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives of formula (I). | 2013-03-14 |
| 20130065920 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS CONTAINING REBAMIPIDE AS AN ACTIVE INGREDIENT - The present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg. | 2013-03-14 |
| 20130065921 | PTEN INHIBITOR OR MAXI-K CHANNELS OPENER - A new PTEN opener or a new opener of a large conductance Ca | 2013-03-14 |
| 20130065922 | NOVEL AMIDES AS FUNGICIDES - Compounds of the general formula (I), wherein the substituents are as defined in claim | 2013-03-14 |
| 20130065923 | SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-heteroaryl bipyrrolidine carboxamides of formula (I). | 2013-03-14 |
| 20130065924 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEURODEGENERATION - A composition and method for the treatment of neurodegeneration and brain-derived neurotrophic factor. The composition and method comprising providing fluoxetine, simvastatin, and optionally, an antioxidant. | 2013-03-14 |
| 20130065925 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE - A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: | 2013-03-14 |
| 20130065926 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1). | 2013-03-14 |
| 20130065927 | FORMS OF DEXLANSOPRAZOLE AND PROCESSES FOR THE PREPARATION THEREOF - Provided is dexlansoprazole propylene glycolate hydrate. Polymorphic forms thereof are also provided. The dexlansoprazole propylene glycolate hydrate maybe such that the propylene glycol component is present in approximately equal proportions of (R) absolute configuration and (S) absolute configuration, or present in predominantly (R) absolute configuration, or predominantly (S) absolute configuration. Salts of dexlansoprazole are also provided. In particular, crystalline dexlansoprazole isopropylammonium salt and crystalline MTBE solvate of dexlansoprazole t-butylammonium salt are provided. Pharmaceutical formulations comprising dexlansoprazole propylene glycolate hydrate are also provided. Furthermore, processes for preparation of dexlansoprazole propylene glycolate hydrate are provided. | 2013-03-14 |
| 20130065928 | BIOMARKERS FOR PI3K-DRIVEN CANCER - Disclosed is the discovery that the mTORC2 complex plays a role in the regulation of PKN3 phosphorylation at the turn motif threonine; and the use of the phosphorylation status of the turn motif threonine of PKN3 as a biomarker. In some embodiments, the phosphorylation status of the turn motif threonine of PKN3 is determined using an antibody that specifically binds to the turn motif threonine of a PKN3 protein, such as an anti-phosphoT860 antibody. In some embodiments, the invention relates to methods for screening compounds that have cancer therapeutic potential, methods for diagnosing cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial, methods for treating a patient suffering from cancer, and methods for determining the effectiveness of a particular treatment regimen. | 2013-03-14 |
| 20130065929 | Use of Pyridoxamine to Treat and/or Prevent Disease Processes - Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. | 2013-03-14 |
| 20130065930 | TOPICAL COMPOSITION - A topical composition comprising: fipronil or a pharmaceutically acceptable salt thereof; at least one surfactant and at least one crystallization inhibitor for the treatment and protection of animals which are infested with parasites. | 2013-03-14 |
| 20130065931 | METHODS FOR REDUCING WIREWORM DAMAGE TO CROPS - Methods and compositions for controlling pests of the order Coleoptera are described herein. Methods of reducing wireworm damage in potatoes by applying a compound or composition disclosed herein in a foliar treatment is also described. | 2013-03-14 |
| 20130065932 | PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER - The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from | 2013-03-14 |
| 20130065933 | PHARMACEUTICAL COMPOSITION FOR PERORAL ADMINISTRATION OF DIINDOLYLMETHANE - The invention relates to pharmacy. It comprises block copolymer pharmaceutical compositions containing 3,3′-diindolylmethane (DIM). The pharmaceutical composition for peroral administration comprises 3,3′-diindolylmethane as an active component and a target additive, the target additive being a block copolymer of oxyethylene and oxypropylene, in which the content of the hydrophobic block is less than 50 mass % and the molecular mass of the hydrophilic block is equal to 2,250 Da or more, at a ratio of the active component to the selected block copolymer varying between 10:1 and 2:1. | 2013-03-14 |
| 20130065934 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES - The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune, inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative. | 2013-03-14 |
| 20130065935 | Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2 - The invention features compounds and methods relating to novel hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters. These analogs are potent and selective inhibitors of ASCT2 and ASCT1-mediated amino acid transport as evidenced by significantly reduced glutamine or alanine transport-associated currents or radiolabeled substrate (amino acid) uptake in | 2013-03-14 |
| 20130065936 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS - The present invention provides method for increasing levels of epoxygenated fatty acids by administration of a phosphodiesterase inhibitor. | 2013-03-14 |
| 20130065937 | NOVEL PRENYLARENE COMPOUND AND USE THEREOF - A compound represented by the general formula (C): | 2013-03-14 |
| 20130065938 | Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer - Methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155 are described. | 2013-03-14 |
| 20130065939 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER - The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer. | 2013-03-14 |
| 20130065940 | DOUBLE-STRANDED RNA MOLECULES WITH STABILITY IN MAMMALIAN BODY FLUID, PREPARATION AND APPLICATION THEREOF - The present invention discloses preparation and application of double-stranded RNA molecules stable in mammalian body fluids. The mammalian-body-fluid-stable RNA molecules disclosed in the present invention are comprised of only unmodifide nucleotides. For the first time, the present invention discloses the applications of mammalian-body-fluid-stable RNA molecules for immunotherapy and siRNA drug development. | 2013-03-14 |
| 20130065941 | COMPOSITIONS AND THEIR USES FOR GENE THERAPY OF BONE CONDITIONS - In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions. | 2013-03-14 |
| 20130065942 | Nucleic Acid-Lipopolymer Compositions - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 2013-03-14 |
| 20130065943 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene. | 2013-03-14 |
| 20130065944 | REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF - The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical and dietetic fields. | 2013-03-14 |
| 20130065945 | NLK AS A MARKER FOR DIAGNOSIS OF LIVER CANCER AND AS A THERAPEUTIC AGENT THEREOF - A novel marker for diagnosis of liver cancer and use thereof are provided. To be specific, a marker for diagnosis of liver cancer using over-expression of NLK (neuro-like kinase) in liver cancer cell is provided, along with a composition for diagnosis of liver cancer, a kit, a microarray, and a method for diagnosing liver cancer using the marker. Additionally, a method for screening a substance to prevent or treat liver cancer by decreasing expression of the marker gene or protein, and a composition for preventing or treating liver cancer including such substance are provided. Accordingly, the NLK gene can be efficiently used as a target for diagnosis and treatment of liver cancer. | 2013-03-14 |
| 20130065946 | Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 - The present invention provides materials and methods related to modulation of mismatch and genomic stability by miR-155. | 2013-03-14 |
| 20130065947 | TREATMENT OF PAR4 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PAR4 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of PAR4, in particular, by targeting natural antisense polynucleotides of PAR4. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PAR4. | 2013-03-14 |
| 20130065948 | NUCLEIC ACID MOLECULES AND METHODS FOR EXCHANGING EXON(S) BY TRANSSPLICING - The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated simple or double trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and to mediate a simple or double trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). | 2013-03-14 |
| 20130065949 | MICRORNA MIRNA-31 AS A THERAPEUTIC APPROACH FOR THE TREATMENT OF CANCER - The present invention generally concerns methods and compositions for treating and/or preventing cancer with microRNAs. In specific embodiments, the present invention encompasses a particular microRNA, microRNA-31, as useful in cancer therapy and/or prevention. Specific cancers may be treated, including at least ovarian, prostate, urothelial, osteosarcoma, and glioblastoma. | 2013-03-14 |
| 20130065950 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 2013-03-14 |
| 20130065951 | COMPOSITIONS AND METHODS RELATED TO MIRNA MODULATION OF NEOVASCULARIZATION OR ANGIOGENESIS - The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed. | 2013-03-14 |
| 20130065952 | TUMOR-SPECIFIC PROMOTER AND ONCOLYTIC VIRUS VECTOR COMPRISING THE SAME - Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer. | 2013-03-14 |
| 20130065953 | PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS - The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided. | 2013-03-14 |
| 20130065954 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS - The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder. | 2013-03-14 |
| 20130065955 | CRYSTALLINE FORMS OF CABAZITAXEL - The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8 | 2013-03-14 |
| 20130065956 | COMPOSITION AND/OR METHOD FOR PREVENTING ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS - Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI. | 2013-03-14 |
| 20130065957 | DICLOFENAC SALT OF TRAMADOL - The present invention relates to a compound of diclofenac-tramadol salt in 1:1 ratio and a pharmaceutical formulation comprising such compound. The present invention also relates to a method for treating a patient with moderate to moderately severe pain. The method comprises: identifying a patient suffering from moderate to moderately severe pain with pain intensity scale of 5-9, and administering to said patient the diclofenac-tramadol salt, in an effective amount. The method is particularly useful in treating postoperative pain after Cesarean, postoperative pain after non-Cesarean surgeries, cancer pain, osteoarthritis pain, or rheumatoid arthritis pain. | 2013-03-14 |
| 20130065958 | METHODS FOR DISINFECTING OR STERILIZING ARTICLES - Disclosed herein are materials and methods for reducing, preventing, or eliminating the biological contamination of surfaces in spaces that are reasonably partitioned, defined or contained. A reagent that includes peroxides or molecules that includes peroxide bonds are contacted with at least one surface of an article. Some of these methods include disinfection within an apparatus and may include the step of volatilizing the peroxide bond containing agent, through, for example, vapour pressure and vaporization or evaporation effects, the addition of volatilization aids, or passive or assisted diffusion at modest temperatures and relatively long exposure times measured in some embodiments on the order of hours, days, or months. In some embodiments a liquid that includes a peroxide moiety is added (for example, during manufacture or subsequently) to a package, container, or any other reasonably partitioned or contained volume and allowed to migrate within the confined space for a period of time sufficient to disinfect the inner surfaces of the container and articles it contains. | 2013-03-14 |
| 20130065959 | SANITIZING MEAT WITH PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS - Methods and compositions for treating items to control microorganisms are provided. The method treats produce by contacting the surface of an item with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water wherein the aqueous solution has a pH from 2.5 to 6.0. | 2013-03-14 |
| 20130065960 | METHOD FOR PRODUCING POWDER MIXTURE - There is provided a method for producing a powder mixture containing an alkali metal salt that exhibits basicity in an aqueous solution (component (A)); at least one type of metal salt selected from the salts of copper, manganese, iron, cobalt and zinc (component (B)); and a compound represented by the following general formula (1) (component (C)), including spraying and mixing an aqueous solution of metal which is an aqueous solution of the aforementioned component (B) with a powder of the aforementioned component (A), and then mixing a powder of the aforementioned component (C) therewith. According to the present invention, it is possible to provide a method for producing a powder mixture which can easily produce a powder mixture that exhibits excellent solubility in water even when containing a basic alkali metal salt and a metal salt: | 2013-03-14 |
| 20130065961 | MODULATION OF PHYSIOLOGICAL PROCESSES AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia. | 2013-03-14 |
